Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis
Objectives. CD40L is a costimulatory molecule and an early activation marker of T-lymphocytes. Based on the hypothesis that activated T-cells may play a role in the pathogenesis of psoriatic arthritis (PsA), we evaluated the level of CD40L expression on T-cells from patients with PsA. Methods. We an...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2007-02, Vol.46 (2), p.227-231 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 231 |
|---|---|
| container_issue | 2 |
| container_start_page | 227 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 46 |
| creator | Daoussis, D. Antonopoulos, I. Andonopoulos, A. P. Liossis, S.-N. C. |
| description | Objectives. CD40L is a costimulatory molecule and an early activation marker of T-lymphocytes. Based on the hypothesis that activated T-cells may play a role in the pathogenesis of psoriatic arthritis (PsA), we evaluated the level of CD40L expression on T-cells from patients with PsA.
Methods. We analysed 12 patients with PsA, six patients with rheumatoid arthritis (RA) and four healthy volunteers. T-cell surface expression of CD40L was evaluated using two-colour flow cytometry in (i) the resting state and (ii) following stimulation with phorbol myristate acetate/ionomycin, with or without ciclosporin (CsA)-mediated inhibition.
Results. Expression of CD40L was significantly increased on activated T-cells from patients with PsA, particularly those with active disease, when compared with normal individuals and patients with RA (mean percentages of CD3+ CD40L+ cells: 23.74, 11.59 and 9.57% for patients with active PsA, patients with RA and healthy volunteers, respectively). CsA-mediated inhibition of CD40L induction was equally effective in all study groups.
Conclusion. CD40L is overexpressed on T-cells from patients with active PsA. This may indicate a role for CD40L in PsA pathogenesis. Larger-scale studies are warranted to address these issues. |
| doi_str_mv | 10.1093/rheumatology/kel229 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68941169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/kel229</oup_id><sourcerecordid>1202731391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-57c7d097aac03de92f1bd951f6cc04c2c389a62de573f361dc053bc74e108c9c3</originalsourceid><addsrcrecordid>eNqN0MtKxDAUBuAgivcnECQIii6qubRps5TxCgNudF0yp6kTbZuak6K-vR1mUHHlKuHwnQs_IQecnXOm5UWY26E10Tf--fPi1TZC6DWyzVMlEialWP_-i3SL7CC-MMYyLotNssVVoXjO8m0yu-8gWIO2ovajDxbR-Y76mk6ueJbS08lVyqZndKxhdO3QmDjKxwRs0yCtg29pb6KzXUT67uKc9uiDGytATYjz4KLDPbJRmwbt_urdJU8314-Tu2T6cHs_uZwmILWOSZZDXjGdGwNMVlaLms8qnfFaAbAUBMhCGyUqm-WylopXwDI5gzy1nBWgQe6Sk-XcPvi3wWIsW4eLQ01n_YClKnTKudIjPPoDX_wQuvG2kutMKaZ4MSK5RBA8YrB12QfXmvBZclYu8i9_518u8x-7Dlejh1lrq5-eVeAjOF4Bg2CaOpgOHP64IhOCicX686XzQ_-vzV-dnaKh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195660618</pqid></control><display><type>article</type><title>Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis</title><source>MEDLINE</source><source>Oxford University Press Journals Current</source><source>Alma/SFX Local Collection</source><creator>Daoussis, D. ; Antonopoulos, I. ; Andonopoulos, A. P. ; Liossis, S.-N. C.</creator><creatorcontrib>Daoussis, D. ; Antonopoulos, I. ; Andonopoulos, A. P. ; Liossis, S.-N. C.</creatorcontrib><description>Objectives. CD40L is a costimulatory molecule and an early activation marker of T-lymphocytes. Based on the hypothesis that activated T-cells may play a role in the pathogenesis of psoriatic arthritis (PsA), we evaluated the level of CD40L expression on T-cells from patients with PsA.
Methods. We analysed 12 patients with PsA, six patients with rheumatoid arthritis (RA) and four healthy volunteers. T-cell surface expression of CD40L was evaluated using two-colour flow cytometry in (i) the resting state and (ii) following stimulation with phorbol myristate acetate/ionomycin, with or without ciclosporin (CsA)-mediated inhibition.
Results. Expression of CD40L was significantly increased on activated T-cells from patients with PsA, particularly those with active disease, when compared with normal individuals and patients with RA (mean percentages of CD3+ CD40L+ cells: 23.74, 11.59 and 9.57% for patients with active PsA, patients with RA and healthy volunteers, respectively). CsA-mediated inhibition of CD40L induction was equally effective in all study groups.
Conclusion. CD40L is overexpressed on T-cells from patients with active PsA. This may indicate a role for CD40L in PsA pathogenesis. Larger-scale studies are warranted to address these issues.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kel229</identifier><identifier>PMID: 16861707</identifier><identifier>CODEN: BJRHDF</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Arthritis, Psoriatic - immunology ; Arthritis, Rheumatoid - immunology ; Biological and medical sciences ; CD40 Ligand - biosynthesis ; CD40 Ligand - blood ; CD8-Positive T-Lymphocytes - immunology ; Cells, Cultured ; Cyclosporine - pharmacology ; Dermatology ; Diseases of the osteoarticular system ; Female ; Humans ; Immunosuppressive Agents - pharmacology ; Inflammatory joint diseases ; Lymphocyte Activation - immunology ; Male ; Medical sciences ; Middle Aged ; Psoriasis. Parapsoriasis. Lichen ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology</subject><ispartof>Rheumatology (Oxford, England), 2007-02, Vol.46 (2), p.227-231</ispartof><rights>The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2006</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Feb 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-57c7d097aac03de92f1bd951f6cc04c2c389a62de573f361dc053bc74e108c9c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,1581,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18522028$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16861707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daoussis, D.</creatorcontrib><creatorcontrib>Antonopoulos, I.</creatorcontrib><creatorcontrib>Andonopoulos, A. P.</creatorcontrib><creatorcontrib>Liossis, S.-N. C.</creatorcontrib><title>Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Objectives. CD40L is a costimulatory molecule and an early activation marker of T-lymphocytes. Based on the hypothesis that activated T-cells may play a role in the pathogenesis of psoriatic arthritis (PsA), we evaluated the level of CD40L expression on T-cells from patients with PsA.
Methods. We analysed 12 patients with PsA, six patients with rheumatoid arthritis (RA) and four healthy volunteers. T-cell surface expression of CD40L was evaluated using two-colour flow cytometry in (i) the resting state and (ii) following stimulation with phorbol myristate acetate/ionomycin, with or without ciclosporin (CsA)-mediated inhibition.
Results. Expression of CD40L was significantly increased on activated T-cells from patients with PsA, particularly those with active disease, when compared with normal individuals and patients with RA (mean percentages of CD3+ CD40L+ cells: 23.74, 11.59 and 9.57% for patients with active PsA, patients with RA and healthy volunteers, respectively). CsA-mediated inhibition of CD40L induction was equally effective in all study groups.
Conclusion. CD40L is overexpressed on T-cells from patients with active PsA. This may indicate a role for CD40L in PsA pathogenesis. Larger-scale studies are warranted to address these issues.</description><subject>Adult</subject><subject>Aged</subject><subject>Arthritis, Psoriatic - immunology</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>Biological and medical sciences</subject><subject>CD40 Ligand - biosynthesis</subject><subject>CD40 Ligand - blood</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cells, Cultured</subject><subject>Cyclosporine - pharmacology</subject><subject>Dermatology</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Inflammatory joint diseases</subject><subject>Lymphocyte Activation - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0MtKxDAUBuAgivcnECQIii6qubRps5TxCgNudF0yp6kTbZuak6K-vR1mUHHlKuHwnQs_IQecnXOm5UWY26E10Tf--fPi1TZC6DWyzVMlEialWP_-i3SL7CC-MMYyLotNssVVoXjO8m0yu-8gWIO2ovajDxbR-Y76mk6ueJbS08lVyqZndKxhdO3QmDjKxwRs0yCtg29pb6KzXUT67uKc9uiDGytATYjz4KLDPbJRmwbt_urdJU8314-Tu2T6cHs_uZwmILWOSZZDXjGdGwNMVlaLms8qnfFaAbAUBMhCGyUqm-WylopXwDI5gzy1nBWgQe6Sk-XcPvi3wWIsW4eLQ01n_YClKnTKudIjPPoDX_wQuvG2kutMKaZ4MSK5RBA8YrB12QfXmvBZclYu8i9_518u8x-7Dlejh1lrq5-eVeAjOF4Bg2CaOpgOHP64IhOCicX686XzQ_-vzV-dnaKh</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Daoussis, D.</creator><creator>Antonopoulos, I.</creator><creator>Andonopoulos, A. P.</creator><creator>Liossis, S.-N. C.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20070201</creationdate><title>Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis</title><author>Daoussis, D. ; Antonopoulos, I. ; Andonopoulos, A. P. ; Liossis, S.-N. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-57c7d097aac03de92f1bd951f6cc04c2c389a62de573f361dc053bc74e108c9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Arthritis, Psoriatic - immunology</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>Biological and medical sciences</topic><topic>CD40 Ligand - biosynthesis</topic><topic>CD40 Ligand - blood</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cells, Cultured</topic><topic>Cyclosporine - pharmacology</topic><topic>Dermatology</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Inflammatory joint diseases</topic><topic>Lymphocyte Activation - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daoussis, D.</creatorcontrib><creatorcontrib>Antonopoulos, I.</creatorcontrib><creatorcontrib>Andonopoulos, A. P.</creatorcontrib><creatorcontrib>Liossis, S.-N. C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daoussis, D.</au><au>Antonopoulos, I.</au><au>Andonopoulos, A. P.</au><au>Liossis, S.-N. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>46</volume><issue>2</issue><spage>227</spage><epage>231</epage><pages>227-231</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><coden>BJRHDF</coden><abstract>Objectives. CD40L is a costimulatory molecule and an early activation marker of T-lymphocytes. Based on the hypothesis that activated T-cells may play a role in the pathogenesis of psoriatic arthritis (PsA), we evaluated the level of CD40L expression on T-cells from patients with PsA.
Methods. We analysed 12 patients with PsA, six patients with rheumatoid arthritis (RA) and four healthy volunteers. T-cell surface expression of CD40L was evaluated using two-colour flow cytometry in (i) the resting state and (ii) following stimulation with phorbol myristate acetate/ionomycin, with or without ciclosporin (CsA)-mediated inhibition.
Results. Expression of CD40L was significantly increased on activated T-cells from patients with PsA, particularly those with active disease, when compared with normal individuals and patients with RA (mean percentages of CD3+ CD40L+ cells: 23.74, 11.59 and 9.57% for patients with active PsA, patients with RA and healthy volunteers, respectively). CsA-mediated inhibition of CD40L induction was equally effective in all study groups.
Conclusion. CD40L is overexpressed on T-cells from patients with active PsA. This may indicate a role for CD40L in PsA pathogenesis. Larger-scale studies are warranted to address these issues.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>16861707</pmid><doi>10.1093/rheumatology/kel229</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2007-02, Vol.46 (2), p.227-231 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68941169 |
| source | MEDLINE; Oxford University Press Journals Current; Alma/SFX Local Collection |
| subjects | Adult Aged Arthritis, Psoriatic - immunology Arthritis, Rheumatoid - immunology Biological and medical sciences CD40 Ligand - biosynthesis CD40 Ligand - blood CD8-Positive T-Lymphocytes - immunology Cells, Cultured Cyclosporine - pharmacology Dermatology Diseases of the osteoarticular system Female Humans Immunosuppressive Agents - pharmacology Inflammatory joint diseases Lymphocyte Activation - immunology Male Medical sciences Middle Aged Psoriasis. Parapsoriasis. Lichen T-Lymphocytes - drug effects T-Lymphocytes - immunology |
| title | Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T06%3A48%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20expression%20of%20CD154%20(CD40L)%20on%20stimulated%20T-cells%20from%20patients%20with%20psoriatic%20arthritis&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Daoussis,%20D.&rft.date=2007-02-01&rft.volume=46&rft.issue=2&rft.spage=227&rft.epage=231&rft.pages=227-231&rft.issn=1462-0324&rft.eissn=1462-0332&rft.coden=BJRHDF&rft_id=info:doi/10.1093/rheumatology/kel229&rft_dat=%3Cproquest_cross%3E1202731391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195660618&rft_id=info:pmid/16861707&rft_oup_id=10.1093/rheumatology/kel229&rfr_iscdi=true |